Clinical trial
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
NCT00439361 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00439361 |
|---|---|
| Title | Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma |
| Official title | Phase-I Study of Bortezomib (VELCADE) Plus ICE (Ifosfamide, Carboplatin, Etoposide) for Patients With Relapsed Classical Hodgkin Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hodgkin Lymphoma, Lymphoma |
| Intervention type | Drug |
| Interventions | Bortezomib, Carboplatin, Etoposide, Ifosfamide, Mesna |
| Enrollment | 14 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Feb 23, 2007 |
| Last update posted | Jul 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: